Roche/Genentech spinal muscular atrophy treatment granted Orphan Drug designation
Dec. 07, 2021 6:23 PM ETRoche Holding AG (RHHBY)RXRXBy: Jonathan Block, SA News Editor1 Comment
- A monoclonal antibody under development from Roche (OTCQX:RHHBY) company Genentech was granted Orphan Drug designation for spinal muscular atrophy.
- The treatment is classified as a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependent manner.
- Genentech currently markets the spinal muscular atrophy treatment Evrysdi (risdiplam).
- Roche inked a collaboration agreement earlier today with Recursion Pharmaceuticals (NASDAQ:RXRX) on neuroscience and oncology.